JP2009521685A - 可溶性ヒトｍ−ｃｓｆ受容体およびその使用 - Google Patents

可溶性ヒトｍ−ｃｓｆ受容体およびその使用 Download PDF

Info

Publication number
JP2009521685A
JP2009521685A JP2008547568A JP2008547568A JP2009521685A JP 2009521685 A JP2009521685 A JP 2009521685A JP 2008547568 A JP2008547568 A JP 2008547568A JP 2008547568 A JP2008547568 A JP 2008547568A JP 2009521685 A JP2009521685 A JP 2009521685A
Authority
JP
Japan
Prior art keywords
cancer
soluble
csf
csfr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008547568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009521685A5 (https=
Inventor
チェン リュー，
マハ デューター−ラインハルト，
ジョン クニチ，
マイケル カバナフ，
Original Assignee
ノバルティス アーゲー
ゾーマ テクノロジー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ゾーマ テクノロジー リミテッド filed Critical ノバルティス アーゲー
Publication of JP2009521685A publication Critical patent/JP2009521685A/ja
Publication of JP2009521685A5 publication Critical patent/JP2009521685A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/53—Colony-stimulating factor [CSF]
    • G01N2333/535—Granulocyte CSF; Granulocyte-macrophage CSF

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2008547568A 2005-12-22 2006-12-21 可溶性ヒトｍ−ｃｓｆ受容体およびその使用 Withdrawn JP2009521685A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75321805P 2005-12-22 2005-12-22
PCT/US2006/048879 WO2007120252A2 (en) 2005-12-22 2006-12-21 Soluble human m-csf receptor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012043540A Division JP2012108155A (ja) 2005-12-22 2012-02-29 可溶性ヒトｍ−ｃｓｆ受容体およびその使用

Publications (2)

Publication Number Publication Date
JP2009521685A true JP2009521685A (ja) 2009-06-04
JP2009521685A5 JP2009521685A5 (https=) 2011-02-10

Family

ID=38609972

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008547568A Withdrawn JP2009521685A (ja) 2005-12-22 2006-12-21 可溶性ヒトｍ−ｃｓｆ受容体およびその使用
JP2012043540A Pending JP2012108155A (ja) 2005-12-22 2012-02-29 可溶性ヒトｍ−ｃｓｆ受容体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012043540A Pending JP2012108155A (ja) 2005-12-22 2012-02-29 可溶性ヒトｍ−ｃｓｆ受容体およびその使用

Country Status (8)

Country Link
US (2) US20100099123A1 (https=)
EP (1) EP1977238B1 (https=)
JP (2) JP2009521685A (https=)
KR (1) KR101358600B1 (https=)
CN (1) CN101379400A (https=)
AU (1) AU2006342119B8 (https=)
CA (1) CA2634945A1 (https=)
WO (1) WO2007120252A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
WO2010062401A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
EP2950098A1 (en) * 2009-07-14 2015-12-02 National Institute of Advanced Industrial Science and Technology Glycan markers as measure of disease state of hepatic diseases
RU2427323C1 (ru) * 2010-02-25 2011-08-27 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ прогнозирования генерализации процесса при злокачественных опухолях костей
MX378336B (es) 2010-05-04 2025-03-10 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
ES2442991B1 (es) * 2012-08-14 2014-11-25 Fundación Md Anderson International España Método para el diagnóstico y/o pronóstico de linfomas
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
AU2015280362B2 (en) 2014-06-23 2021-03-04 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
PT3212670T (pt) 2014-10-29 2021-02-15 Bristol Myers Squibb Co Terapêutica de combinação para cancro
EA201791421A1 (ru) 2014-12-22 2017-10-31 Файв Прайм Терапьютикс, Инк. Антитела против csf1r для лечения pvns
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
SG11202001606XA (en) 2017-09-13 2020-03-30 Five Prime Therapeutics Inc Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03500879A (ja) * 1987-10-23 1991-02-28 森永乳業株式会社 ｃ―ｆｍｓ癌原遺伝子の過剰発現によって特徴づけられた癌の処置用組成物および方法
JPH0967400A (ja) * 1995-08-31 1997-03-11 Toray Ind Inc モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用
WO2004075775A2 (en) * 2003-02-24 2004-09-10 Sugen, Inc. Treatment of excessive osteolyisis with indolinone compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US6610484B1 (en) * 1999-01-26 2003-08-26 Cytyc Health Corporation Identifying material from a breast duct
WO2004045532A2 (en) * 2002-11-15 2004-06-03 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03500879A (ja) * 1987-10-23 1991-02-28 森永乳業株式会社 ｃ―ｆｍｓ癌原遺伝子の過剰発現によって特徴づけられた癌の処置用組成物および方法
JPH0967400A (ja) * 1995-08-31 1997-03-11 Toray Ind Inc モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用
WO2004075775A2 (en) * 2003-02-24 2004-09-10 Sugen, Inc. Treatment of excessive osteolyisis with indolinone compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5008023168; ＲＡＯ　Ｑ: ＣＨＩＮＥＳＥ　ＪＯＵＲＮＡＬ　ＯＦ　ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖ１３　Ｎ３, 2001, Ｐ１８５-１８９ *
JPN5008023169; ＳＴＯＲＧＡ　Ｄ: ＩＮＴＥＲＮＡＴＩＯＮＡＬ　ＪＯＵＲＮＡＬ　ＯＦ　ＥＸＰＥＲＩＭＥＮＴＡＬ　ＰＡＴＨＯＬＯＧＹ Ｖ７３　Ｎ４, 1992, Ｐ５２７-５３３ *
JPN5008023170; ＢＡＩＯＣＣＨＩ　Ｇ: ＣＡＮＣＥＲ Ｖ６７　Ｎ４, 1991, Ｐ９９０-９９６ *
JPN5008023171; ＫＡＵＭＡ　Ｓ　Ｗ: ＪＯＵＲＮＡＬ　ＯＦ　ＣＬＩＮＩＣＡＬ　ＥＮＤＯＣＲＩＮＯＬＯＧＹ　ＡＮＤ　ＭＥＴＡＢＯＬＩＳＭ Ｖ７３　Ｎ４, 19910101, Ｐ７４６-７５１, ＥＮＤＯＣＲＩＮＥ　ＳＯＣＩＥＴＹ *

Also Published As

Publication number Publication date
AU2006342119A1 (en) 2007-10-25
JP2012108155A (ja) 2012-06-07
WO2007120252A3 (en) 2008-10-09
US20140030738A1 (en) 2014-01-30
EP1977238A2 (en) 2008-10-08
KR20080085054A (ko) 2008-09-22
AU2006342119B8 (en) 2013-05-09
AU2006342119A8 (en) 2013-05-09
AU2006342119B2 (en) 2013-01-10
CA2634945A1 (en) 2007-10-25
EP1977238B1 (en) 2016-09-28
CN101379400A (zh) 2009-03-04
KR101358600B1 (ko) 2014-02-06
WO2007120252A2 (en) 2007-10-25
US20100099123A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
JP2012108155A (ja) 可溶性ヒトｍ−ｃｓｆ受容体およびその使用
JP6411379B2 (ja) レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
KR102057438B1 (ko) 엽산 수용체 알파-발현 암에 대한 진단 및 예후 마커로서의 엽산 수용체 알파
JP6038128B2 (ja) レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
US20250172572A1 (en) Noninvasive method to quantify kidney function and functional decline
EP2895863B1 (en) New biomarkers for the diagnosis and/or prognosis of clear cell renal cell carcinoma
JP2023508023A (ja) Ｃｘｃｌ１０結合タンパク質及びその使用
JP2019518970A (ja) 腎臓癌を患う対象の癌治療に対する感受性を予測するための方法およびキット
CN103558391A (zh) 可溶性人m-csf受体及其应用
AU2012261609A9 (en) Soluble human M-CSF receptor and uses thereof
MX2008007881A (es) Receptor m-csf humano soluble y usos del mismo
CN110687284A (zh) 检测血清中six2自身抗体的试剂的应用
JP2008537101A (ja) 薬物応答を予測するための前立腺特異的抗原の使用
JP2024523546A (ja) がんの再発の予測
WO2014023819A1 (en) Methods for predicting the survival time of a patient suffering from a glioblastoma
US20120301879A1 (en) Novel use of ca-125
CN110546510A (zh) 预后方法和在所述方法中有用的试剂盒
KR20150004683A (ko) 혈액 단백질 바이오마커를 이용한 류마티스 관절염 진단용 키트 및 이를 이용한 류마티스 관절염 진단 방법
MX2008010297A (en) Detection of cancer by elevated levels of bcl-2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120123

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130531

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130607

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130731